论文部分内容阅读
目的观察补肾益肺解毒方对Wista大鼠肺癌干预作用及其机理,为临床上应用补肾益肺解毒方防治肺癌提供客观依据。方法 SPF级Wista大鼠72只,随机分为3组,分组后建立肺癌模型,观察补肾益肺解毒方对肺癌大鼠一般情况,肺指数及脾指数的影响。运用免疫组化技术,测定肺癌组织中K-ras、p21蛋白的表达。结果部分大鼠出现肺部肿瘤,部分出现支气管上皮不典型增生,模型组大鼠肺癌(包括癌前病变)发生率高于用药组;模型组大鼠脾指数低于用药组,肺指数则高于用药组(P<0.05)。中药高剂量组可降低大鼠癌基因K-ras的表达,与肺癌模型组相比有显著差异(P<0.05);中药高剂量组大鼠抑癌基因p21表达高于模型组(P<0.05)。结论补肾益肺解毒方能增强机体的免疫功能,抑制大鼠肺癌的发生、发展,为临床进一步应用提供了科学依据。
Objective To observe the effect and mechanism of Bushen Yifefei Jiedu Fang on lung cancer in Wistar rats and provide an objective basis for the prevention and treatment of lung cancer with Bushen Yifei Jiedu Fang. Methods Seventy two Wistar rats with SPF grade were randomly divided into three groups. The lung cancer model was established after grouping. The effects of Bushen Yifeng Jiedu Fang on the general condition, lung index and spleen index of lung cancer rats were observed. Immunohistochemistry was used to detect the expression of K-ras and p21 in lung cancer tissues. Results Some of the rats developed pulmonary tumors and some showed bronchial epithelial dysplasia. The incidence of lung cancer (including precancerous lesion) in the model group was higher than that of the drug-treated group. The spleen index of the model group was lower than that of the drug-treated group, while the pulmonary index In the medication group (P <0.05). Compared with model group, the expression of K-ras mRNA in rat high-dose group was significantly lower than that in model group (P <0.05) ). Conclusion Bushen Yifeujiedu can enhance the body’s immune function, inhibit the occurrence and development of lung cancer in rats, and provide a scientific basis for further clinical application.